New Research Reports

While near-term demand remains uneven across international markets, management commentary suggests gradual stabilization supported by normalization in freight, moderating raw material costs, and improved replacement demand.

MMFS shared its long-term aspiration to position itself as the most trusted financial services partner for Bharat, leveraging its over three-decade operating history, deep rural presence across 500k villages, and a 12m strong customer base.

Order inflow grew 13.6% YoY to Rs. 2,217.10cr, due to a 16% growth in the railway and metro segment, 40% in the renewables (wind and solar) segment and 10% in the industries segment. However, order inflows declined 43% in the transmission...

Tube Investments posted resilient performance in Q2FY26, underpinned by strong growth across key segments. Management reiterated that diversification remains a core advantage, with momentum supported by new specialised bike launches and the scaling up of EV platforms. The upcoming railway business and the addition of new verticals under TI Medical further enhance long-term visibility. With capex planned across both established and emerging divisions, TII is well-placed to maintain double- digit growth and reinforce its position in the industrial, power systems, and clean mobility markets....

Ashok Leyland enters H2FY26 on a strong footing, supported by improving freight activity, GST-led demand uplift, and a healthy order environment across trucks, buses and LCVs.

*over or under performance to benchmark index Bharat Heavy Electricals Ltd (BHEL), a public sector entity, is India's largest engineering company. It supplies power plant equipment such as gas turbines, generators, thermal sets, diesel shunters, turbo sets, hydro sets, power transformers, switchgears, circuit breakers and boilers. It also manufactures compressors, valves, rectifiers, pumps, capacitors and oil rigs, and undertakes castings and forgings. BHEL's Q2FY26 revenue increased 14.1% YoY to Rs. 7,512cr, driven by an 18.0%...

PB Fintech is a dominant digital marketplace in both insurance and consumer credit—two sectors benefiting from rising financial awareness, digitalization, and significant under-penetration.

We have rolled forward our valuation to Sept’27 estimates. We value Glenmark Pharma at 25.0x Sept’27 EPS implying a target price of INR 2,300.

EXID's 2QFY26 PAT of INR2.2b came in well below our estimate of INR3.2b on account of lower-than-expected revenue. Revenue was mainly affected by channel destocking in segments like auto replacement, UPS and solar and weak demand in home UPS due to extended monsoon.

Glenmark Pharma (GNP) delivered a miss on 2QFY26 earnings, adjusted for a one-time upfront payment received from Abbvie. The miss was largely driven by a severe impact on the domestic formulation (DF) business following the GST transition.